Opinion|Videos|January 9, 2025
Phase 3 ARANOTE Study of ADT + Darolutamide
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the efficacy of this combination therapy in a patient population with newly diagnosed mHSPC. He compares its design and objectives with other established ADT plus androgen receptor pathway inhibitor (ARPI) doublet regimens such as LATITUDE, STAMPEDE D, ENZAMET, ARCHES, and TITAN, and how the study’s results, particularly its efficacy data, compare with those from other trials using abiraterone, enzalutamide, and apalutamide in the first-line setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss the design, population, and objectives of the ARANOTE study of ADT plus+ darolutamide for mHSPC. How do the study’s design and population compare with those of other established ADT + plus ARPI doublet regimens (ie, LATITUDE, STAMPEDE D, ENZAMET, ARCHES, TITAN)?
- Please review the efficacy data from ARANOTE. How do the results compare with those of other ADT plus + ARPI combination regimens available as 1L first-line therapy for mHSPC?
- ARANOTE (ADT + darolutamide [DARO])
- Which efficacy data points from this study stand out to you
- LATITUDE/STAMPEDE-G (ADT + abiraterone [ABI]/prednisone)
- ENZAMET/ARCHES (ADT + enzalutamide [ENZA])
- TITAN (ADT + apalutamide [APA])
- ARANOTE (ADT + darolutamide [DARO])
Advertisement
Related to this article
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5